Therapeutical modulation of plasmacytoid dendritic cells in experimental arthritis.
Fiche publication
Date publication
août 2017
Journal
Arthritis & rheumatology (Hoboken, N.J.)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAHRAM Siamak, Dr CHAN Susan, Dr KASTNER Philippe, Dr KIRSTETTER Peggy, Dr MUELLER Christopher, Dr FLACHER Vincent
Tous les auteurs :
Nehmar R, Alsaleh G, Voisin B, Flacher V, Mariotte A, Saferding V, Puchner A, Niederreiter B, Vandamme T, Schabbauer G, Kastner P, Chan S, Kirstetter P, Holcmann M, Mueller C, Sibilia J, Bahram S, Blüml S, Georgel P
Lien Pubmed
Résumé
The role of plasmacytoid dendritic cells (pDCs) and type I Interferons in rheumatoid arthritis (RA) remains controversial. To explore their contribution to RA pathogenesis, we induced experimental arthritis in various animal models of pDC depletion. We also monitored the effect of localized pDC recruitment and activation on joint inflammation and bone damage.
Mots clés
Adjuvants, Immunologic, pharmacology, Aminoquinolines, pharmacology, Animals, Arthritis, Experimental, genetics, Arthritis, Rheumatoid, genetics, Cytokines, drug effects, Dendritic Cells, drug effects, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Gene Expression Profiling, Humans, Ikaros Transcription Factor, genetics, Imiquimod, Interferon Type I, drug effects, Membrane Glycoproteins, genetics, Mice, Mice, Knockout, Mice, Transgenic, Reverse Transcriptase Polymerase Chain Reaction, Toll-Like Receptor 7, genetics, Tumor Necrosis Factor-alpha, genetics